Global Glomerulonephritis Research 2025, Forecast To 2034
26 Mar, 2025
What Has Been the Growth of the Glomerulonephritis Market So Far?
The glomerulonephritis market has seen considerable growth due to a variety of factors.
• The market size for glomerulonephritis has been experiencing robust growth in the past few years. It is projected to expand from $11.06 billion in 2024 to $11.64 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%.
This growth over the historical period can be credited to factors such as an increase in kidney diseases, more instances of conditions like post-streptococcal glomerulonephritis, elevated research and development activites, an uptick in kidney failure incidence, and a heightened awareness about kidney-related diseases.
How Will the Glomerulonephritis Market?
The glomerulonephritis market is expected to maintain its strong growth trajectory in upcoming years.
• There is projected to be a substantial increase in the glomerulonephritis market in the coming years, with an estimated value of $14.14 billion and a 5.0% compound annual growth rate by 2029. The anticipated growth during this period is largely due to an increase in diabetes cases, an ageing population, higher healthcare spending, a surge in dialysis patients, and the growing incidence of autoimmune diseases. The industry is projected to be shaped by trends including the introduction of new treatments and therapies, enhancement in diagnostic technology, new therapeutic approaches, collaborations among companies, and the use of intravenous immunoglobulin therapy.
Which Factors Are Boosting Growth In The Glomerulonephritis Market?
The escalating occurrence of kidney anomalies is perceived to stimulate the expansion of the glomerulonephritis market in the future. When referring to kidney anomalies, one refers to an array of conditions that impact the kidneys' structure or function, resulting in deficient filtration, elimination of waste, and maintenance of fluid balance. The escalating occurrence of kidney anomalies can be attributed to elements such as ageing communities, heightened levels of chronic ailments such as diabetes and hypertension, and lifestyle decisions. Kidney anomalies stimulate glomerulonephritis as they trigger immune system failures, chronic inflammation, or structural damages leading to hindered kidney filtration and function. In December 2024, for example, as reported by the Australian Institute of Health and Welfare, a governmental agency based in Australia, rates of mortality due to chronic kidney disease (CKD) surged by 4.2% in 2021 and 6.2% in 2022. During 2021–22, CKD was evident in roughly 2 million hospital admissions, accounting for 18% of all hospital admissions in Australia. Consequently, the escalating occurrence of kidney anomalies will catalyze the expansion of the glomerulonephritis market.
What Key Areas Define The Segmentation Of The Global Glomerulonephritis Market?
The glomerulonephritis market covered in this report is segmented –
1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis
2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis
3) By Treatment: Medication, Surgery, Dialysis, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome
2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis
What Trends Are Shaping The Glomerulonephritis Market?
Leading businesses involved in the glomerulonephritis marketplace are concentrating on creating progressive non-immunosuppressive cures in an effort to address unmet medical requirements and enhance patient results. These treatments are intended not to suppress or weaken the immune system, allowing for the treatment of conditions without negatively impacting immune functionality. For instance, Travere Therapeutics Inc., a biopharmaceutical company from the US, rolled out FILSPARI (sparsentan) in September 2024. This drug, which gained FDA approval for treating IgA nephropathy, a form of kidney disease, stands out as the only non-immunosuppressive cure proven to significantly decelerate kidney function deterioration in these patients. The authorization of FILSPARI signals a major advancement in the treatment of IgA nephropathy, the most widespread type of primary glomerulonephritis. It provides a fresh alternative for patients who had been lacking choices in the past. This authorization is an affirmation of Travere's dedication to enhancing patient outcomes in the area of kidney disease.
Who Are the Key Players In The Glomerulonephritis Market?
Major companies operating in the glomerulonephritis market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca PLC
• Novartis International AG
• Eli Lilly and Company
• Asahi Kasei Medical Co. Ltd.
• Boehringer Ingelheim International GmbH
• DaVita Inc.
• Biogen Inc.
• Merit Medical Systems Inc.
• Apellis Pharmaceuticals Inc.
• MorphoSys AG
• Travere Therapeutics Inc.
• Vera Therapeutics Inc.
• Calliditas Therapeutics AB
• Omeros Corporation
• Otsuka Pharmaceutical Co. Ltd.
• Aurinia Pharmaceuticals Inc.
• Alexion Pharmaceuticals Inc.
• NovelMed Therapeutics Inc.
What Is The Most Dominant Region In The Glomerulonephritis Market?
North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.